Sacubitril/Valsartan

ApprovedSmall molecule

Sacubitril/Valsartan is one of 243 small molecule programs targeting Coronary Artery Disease. It is currently in Approved.

Indications

Total Trials

Active Trials

242

Competitors

Pipeline

Status by Indication[3][1]

Indication

Coronary Artery DiseaseActive, not recruiting

Left Ventricular HypertrophyActive, not recruiting

Mitral RegurgitationActive, not recruiting

Essential HypertensionActive, not recruiting

MortalityActive, not recruiting

Physical ActivityActive, not recruiting

HypertensionActive, not recruiting

Breast CancerActive, not recruiting

Heart FailureActive, not recruiting

Hypertrophic CardiomyopathyActive, not recruiting

Coronary Artery DiseaseApproved

Active, not recruiting

Left Ventricular HypertrophyApproved

Active, not recruiting

Mitral RegurgitationPreclinical

Active, not recruiting

Essential HypertensionPhase 3

Active, not recruiting

MortalityApproved

Active, not recruiting

Physical ActivityApproved

Active, not recruiting

HypertensionPhase 2

Active, not recruiting

Breast CancerPhase 2

Active, not recruiting

Heart FailurePreclinical

Active, not recruiting

Hypertrophic CardiomyopathyPhase 2

Active, not recruiting

Competition

Competitive Landscape

2828 competitors in Breast Cancer

#DrugCompanyPhaseTrials

Sacubitril/Valsartan

Novartis

Approved

1 2

Avastin

BBio-Thera Solutions

Preclinical

153 3

Nolvadex

SSan Diego Pacific Oncology & Hematology Associates

Preclinical

78 4

Cymbalta

Alnylam Pharmaceuticals

Preclinical

3 5

Voltaren

Novartis

Preclinical

1 6

Zinecard

CChildren's Oncology Group

Preclinical

2 7

Effexor

WWyeth-Lederle Vaccines

Preclinical

2 8

Recentin

NNational Cancer Institute (NCI)

Preclinical

2 9

Avastin

Roche

Preclinical

4 10

Zoladex

Luye Pharma Group Ltd.

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2026

Post-ApprovalRecruiting

Treatment

NCT06218199

Q1 2027

Phase 3Not yet recruiting

Essential Hypertension

NCT06716970

Q2 2027

Post-ApprovalRecruiting

Coronary Artery Disease

NCT06917664

Clinical

Trials by Indication[1]

Heart Failure16 trials

Sacubitril/Valsartan Treated Adult Patients With Chronic Heart Failure

Completed· Novartis logo

Novartis··NCT05613140·9,230 enrolled

Comparison of BNP and NT-proBNP in the Management of Patients With Chronic and Acute Heart Failure

Unknown status·UUnity Health Toronto·N/A·NCT04107220·300 enrolled

Patient Reported Outcomes inVestigation Following Initiation of Drug Therapy With Entresto (Sacubitril/Valsartan) in Heart Failure

Completed· Novartis logo

Novartis··NCT03387163·402 enrolled

Show 13 more trials

Sacubitril/Valsartan in Patients With Prosthetic Heart Valves With Heart Failure and Reduced Ejection Fraction

Recruiting·KKafrelsheikh University·N/A·NCT07192341·220 enrolled

Efficacy and Safety of Sacubitril/Valsartan in African American Patients With Heart Failure With Reduced Ejection Fraction

Unknown status·MMethodist Health System··NCT05168787·352 enrolled

Prospective Monitoring of Angiotensin Receptor Neprilysin Inhibitor in Older Adults With Heart Failure and Frailty

Unknown status·—··NCT04743063·40,000 enrolled

Replication of the PARADIGM-HF Heart Failure Trial in Healthcare Claims Data.

Completed·—··NCT04736433·6,066 enrolled

Real World Experience in Heart Failure With Reduced Ejection Fraction (HFrEF) Patients Treated With sAc/vaL.

Completed· Novartis logo

Novartis··NCT05448872·924 enrolled

Safety and Tolerability of Sacubitril/Valsartan in Heart Failure Patient With Reduced Ejection Fraction

Completed·NNational Institute of Cardiovascular Diseases, Pakistan·Phase 4·NCT05387967·121 enrolled

Comparison of Sacubitril/Valsartan Versus Enalapril on Effect on NT-proBNP in Patients Stabilized From an Acute Heart Failure Episode.

Completed· Novartis logo

Novartis·Phase 4·NCT02554890·887 enrolled

A Proof of Concept and Dose-finding Study of XXB750 in Patients With Heart Failure

Terminated· Novartis logo

Novartis·Phase 2·NCT06142383·136 enrolled

A Cohort Study to Compare the Hospitalization Between Naive Sacubitril/Valsartan and Naive ACEi/ARBs Heart Failure Patients With Reduced Ejection Fraction Using Secondary US Electronic Health Records Data

Completed· Novartis logo

Novartis··NCT05096143·42,269 enrolled

Role of Sacubitril/Valsartan in Improving Provider Performance in Managing Heart Failure Under Medicare Alternative Payment Models

Completed· Novartis logo

Novartis··NCT05096039·1,614,719 enrolled

PAtient RegisTry Assessing Effectiveness and Safety of HEart Failure treatmeNt With LCZ696 acrOss CaNada

Completed· Novartis logo

Novartis··NCT02957409·1,009 enrolled

A Safety Study of Sacubitril/Valsartan in Japanese Pediatric Patients With Heart Failure Due to Systemic Left Ventricle Systolic Dysfunction Who Have Completed CLCZ696B2319E1 Study

Completed· Novartis logo

Novartis·Phase 3·NCT06149104·8 enrolled

Sacubitril/Valsartan in Heart Failure With Reduced Ejection Fraction Patients: a Real World Study in India

Completed· Novartis logo

Novartis··NCT04735354·268 enrolled

Hypertension3 trials

Effect of LCZ696 on Urinary Microalbumin and Pulse Wave Velocity in Perimenopausal Patients With Hypertension

Unknown status·LLanZhou University·N/A·NCT04800081·264 enrolled

A Study to Evaluate the Effect of LCZ696 on Aortic Stiffness in Subjects With Hypertension

Completed· Novartis logo

Novartis·Phase 2·NCT01870739·115 enrolled

Effects and Safety of Sacubitril/Valsartan on Refractory Hypertension

Unknown status·SSun Yat-Sen Memorial Hospital of Sun Yat-Sen University·Phase 3·NCT05545059·138 enrolled

Essential Hypertension2 trials

Sacubitril/Valsartan Treats Patients With Essential Hypertension and Type 2 Diabetic Nephropathy

Not yet recruiting·SSichuan Academy of Medical Sciences·Phase 4·NCT06501651·297 enrolled

QR12000 Compound Tablets in Patients with Moderate to Severe Essential Hypertension

Not yet recruiting·WWuhan Createrna Science and Technology Co., Ltd·Phase 3·NCT06716970·810 enrolled

Treatment2 trials

Early Treatment of ARNI on Myocardial Remodeling and Progress

Unknown status·RRenJi Hospital·Phase 4·NCT04342351·280 enrolled

Diuretics vs. Afterload Reduction for Treatment of HeartLogic Alerts

Recruiting·HHeart Center Research, LLC·Phase 4·NCT06218199·80 enrolled

HFpEF2 trials

Enhancing the Natriuretic Peptide System in HFpEF

Enrolling by invitation·HHorng Chen·Phase 1/2·NCT05279742·60 enrolled

Changes in NT-proBNP, Safety, and Tolerability in HFpEF Patients With a WHF Event (HFpEF Decompensation) Who Have Been Stabilized and Initiated at the Time of or Within 30 Days Post-decompensation (PARAGLIDE-HF)

Completed· Novartis logo

Novartis·Phase 3·NCT03988634·467 enrolled

15 more indications

Hypertrophic Cardiomyopathy2 trials

Lifestyle and Pharmacological Interventions in Hypertrophic Cardiomyopathy

Completed·NNewcastle-upon-Tyne Hospitals NHS Trust·Phase 2/3·NCT05366101·168 enrolled

Sacubitril/Valsartan vs Lifestyle in Hypertrophic Cardiomyopathy

Completed·NNewcastle University·Phase 2·NCT03832660·168 enrolled

Dialysis Patients1 trial

Sacubitril/Valsartan for CKD5 Stage Dialysis Patients

Completed·RRuijin Hospital·Phase 4·NCT05243199·330 enrolled

Systolic Dysfunction1 trial

The Effects of Sacubitril/Valsartan Compared to Valsartan on LV Remodelling in Asymptomatic LV Systolic Dysfunction After MI

Completed·NNHS Greater Glasgow and Clyde·Phase 3·NCT03552575·93 enrolled

Pediatric Patients1 trial

Open-label Extension Study to Evaluate Long-term Safety of Sacubitril/Valsartan in Pediatric Patients With HF

Completed· Novartis logo

Novartis·Phase 3·NCT03785405·216 enrolled

ALS1 trial

Pulmonary Artery Pressure Reduction With ENTresto (Sacubitril/Valsartan)

Terminated·—·Phase 4·NCT02788656·4 enrolled

Breast Cancer1 trial

Prevention of Cardiac Dysfunction During Breast Cancer Therapy

Completed·TTorbjorn Omland·Phase 2·NCT03760588·138 enrolled

Coronary Artery Disease1 trial

Treatment of Moderate Ischemic Mitral Regurgitation in Patients With Coronary Artery Disease

Recruiting·CChina National Center for Cardiovascular Diseases·Phase 4·NCT06917664·220 enrolled

Mortality1 trial

Efficacy and Safety of Sacubitril/Valsartan Compared With Enalapril on Morbidity, Mortality, and NT-proBNP Change in Patients With CCC

Completed· Novartis logo

Novartis·Phase 4·NCT04023227·918 enrolled

Left Ventricular Hypertrophy1 trial

Sacubitril/Valsartan Versus Amlodipine in Hypertension and Left Ventricular Hypertrophy.

Unknown status·SShanghai Jiao Tong University School of Medicine·Phase 4·NCT04929600·120 enrolled

Mitral regurgitation1 trial

ARNI Combined With SGLT2 Inhibitors on Functional Mitral Regurgitation Remodeling

Recruiting·RRehab Werida··NCT07379788·180 enrolled

Physical Activity1 trial

Study on the Effects of Sacubitril/Valsartan on Physical Activity and Sleep in Heart Failure With Reduced Ejection Fraction Patients.

Completed· Novartis logo

Novartis·Phase 4·NCT02970669·140 enrolled

Metabolism1 trial

Glucagon-like Peptide-1 Metabolism and Acute Neprilysin Inhibition

Suspended·UUniversity of Pennsylvania·Phase 3·NCT03508739·25 enrolled

Double-blind1 trial

A Randomized, Double-blind Controlled Study Comparing LCZ696 to Medical Therapy for Comorbidities in HFpEF Patients

Completed· Novartis logo

Novartis·Phase 3·NCT03066804·2,572 enrolled

Endothelial Function1 trial

Comparing ARNI With ACE Inhibitor on Endothelial Function

Withdrawn·—·Phase 4·NCT03119623

Unspecified1 trial

Open-label Extension Study for CLCZ696G2301 (PARADISE-MI)

Withdrawn· Novartis logo

Novartis·Phase 3·NCT04637555

Sources

References

[1]
ClinicalTrials.gov — 41 trial records for Sacubitril/Valsartan. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Sacubitril/Valsartan compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Sacubitril/Valsartan. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Novartis company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Approved[1]
Company: Novartis

Sacubitril/Valsartan

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2026

Q1 2027

Q2 2027

Trials by Indication[1]

Heart Failure16 trials

Hypertension3 trials

Essential Hypertension2 trials

Treatment2 trials

HFpEF2 trials

Hypertrophic Cardiomyopathy2 trials

Dialysis Patients1 trial

Systolic Dysfunction1 trial

Pediatric Patients1 trial

ALS1 trial

Breast Cancer1 trial

Coronary Artery Disease1 trial

Mortality1 trial

Left Ventricular Hypertrophy1 trial

Mitral regurgitation1 trial

Physical Activity1 trial

Metabolism1 trial

Double-blind1 trial

Endothelial Function1 trial

Unspecified1 trial

References

Drug Info

Quick Facts

Related News